WP5 reached a very important milestone, the interim agreement of the consortium on EU-OPENSCREEN’s future services, scope and strategy, which affects the Preparatory Phase project as a whole.
- Development of a refined user concept.
- Refinement of the EU-OPENSCREEN strategy.
- Development of a construction plan for the EU-OPENSCREN infrastructure.
- Agreement on a Code of Conduct for the operation of the future EU-OPENSCREEN infrastructure.
- Agreement on a business plan for the construction and operational phase.
| DELIVERABLE | DUE DATE | DISSEMINATION |
| D5.1 Report on survey of existing infrastructures | April 2011 | Public [click here] |
| D5.2 Report on user survey | April 2011 | Public [click here] |
| D5.3 Report on refined user service concept and portfolio | October 2011 | Public [click here] |
| D5.4 Impact study | January 2012 | Public [click here] |
| D5.5 Report on the refined EU-OPENSCREEN strategy | April 2012 | Public [click here] |
| D5.6 Proposal of a draft frame for the EU-OPENSCREEN infrastructure | October 2012 | Restricted |
| D5.7 Code of Conduct document | October 2012 | Public [click here] |
| D5.8 Proposal for a layout of the EU-OPENSCREEN infrastructure | February 2013 | Restricted |
| D5.9 Construction plan | April 2013 | Restricted |
| D5.10 Business plan | October 2013 | Restricted |
| NAME | AFFILIATION | CONTACT |
| Philip Gribbon (Chair) | European ScreeningPort | Philip.Gribbon@screeningPort.com |
| Jeremy Everett | University of Greenwich | J.R.Everett@greenwich.ac.uk |
| Thierry Langer | Prestwick Chemical | Thierry.langer@prestwickchemical.fr |
| Steve Rees | AstraZeneca | steve.rees@astrazeneca.com |
| Ulrich Stilz | Sanofi Aventis | Ulrich.Stilz@sanofi-aventis.com |
The EU-OPENSCREEN Strategy Group is chaired by Dr James Inglese, Deputy Director of the NIH Chemical Genomics Centre at the National Human Genome Research Institute, National Institutes of Health (USA).